Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate
Data(s) |
06/07/1996
|
---|---|
Resumo |
Background: Fluticasone propionate was introduced in 1993 in the UK as a potentially safer inhaled corticosteroid than those already in use. The efficacy and safety of fluticasone has been established at recommended doses of 200 µg/day, but not at the higher doses that are often used. <br/><br/>Methods: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one. <br/><br/>Findings: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. In one case the growth rate and cortisol response returned to normal 9 months after the fluticasone dose was reduced to 500 µg/day. <br/><br/>Interpretation: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur. |
Formato |
application/pdf |
Identificador | |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/restrictedAccess |
Fonte |
Todd , G , Dunlop , K , McNaboe , J , Ryan , M F , Carson , D & Shields , M D 1996 , ' Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate ' Lancet , vol 348 , no. 9019 , pp. 27-29 . DOI: 10.1016/S0140-6736(96)03339-9 |
Tipo |
article |